Replies to post #41242 on SiNtx Technologies Inc (SINT)

[boston745]

Mantia says investors can also evaluate shareholder value through softer measures such as innovation and competitive dynamics, "which are harder to measure but can be just as important."

Sintx has taken shareholder investment and is creating products. Assuming those products create more value in the end than the cost to produce them, 270m, then shareholder value is created. Ive said many times that Sintx product portfolio is worth more than 230m that Zimmer paid to acquire Implex; Implex being an ortho materials company comparable to Sintx but with an inferior material and market reach. I even asked Joev2 if he thought that Sintx IP could be justifiably worth more than $1 billion for which he will not comment. Thats where management has created shareholder value. That intrinsic value not reflected by the markets representing value investment opportunity on the market side. However due to a short and distort campaign, investors need to participate in shareholder rights offerings to protect their investment until the day Sintx's IP value is finally unlocked.

For example, a technology company with a strong patent portfolio may be seen as more valuable due to its ability to prevent competitors from copying its technology. Similarly, patents can generate licensing revenue, bolstering a company's financial position. Understanding the strategic value of patents and leveraging them efficiently can positively impact a company's valuation, making it an important aspect to consider in the evaluation of a business.

Currently Sonny is ramping up his companies patent portfolio. The number of patent applications jumped from 50s to 140s in the span of a year. This is where Sintx shareholder value is. At some point, it seems coming soon, Sintx will need to start capitalizing on some of these patents. Most of the patents are likely procedural or repetitive covering different markets. Still, there will be core set that represent most of the companies value. This value is not reflected by the companies balance sheet outside of its accumulated deficit.

You contend that shareholder value is simply based on equity and stockprice based on the quote you posted. Sintx IP value is not reflected on Sintx's balance sheet as an asset and thus you cannot see value being created on paper. Stockholders accumulated deficit does give us an idea of the value but only if that value is worth more than the companies deficit. Again i show rationale for Sintx IP being worth more, significantly more, than its accumulated deficit.
Sintx stockprice does not even reflect Sintx book value representing a value investment opportunity without even factoring in IP. This is, in part, a problem created by a conspiracy of hedge funds shorting and distorting Sintx for 9 years.
What will end up happening, is all that value being created on the IP side, when finally unlocked, will come flooding into the market and SINT will skyrocket. What should have happened over the years is that value should have gradually increased SINT price as more value was created in the companies IP. Shareholder value is locked up for some reason. Its there but not obvious unless you do your research.

I go into evidence of a short and distort scheme going on for 9 years below. In addition to that i show that Sintx IP is worth at minimum $230m, representing a significant value opportunity over Sintx current valuation. In reality Sintx material portfolio is worth significantly more than that because Sintx main material represents a disruptive product that could one day dominate the ortho markets as well as penetrate several other markets!

========================================

This posts shows that there is a family of funds connected to the Anson Group and how those funds took turns participating in Sintx stock offerings over the years. A conspiracy of shorting and distorting.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174597546

This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544

I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472

========================================

The Value being created at Sintx can be seen in the following posts and links:

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.

https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883

========================================

Sintx valuation should be greater than $230m based on comparable company:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174491281

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies

Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/

Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779